See our mission in action as we hear from medical oncologist and Komen Scholar Bryan Schneider, MD, and discuss the ways Komen North Texas is impacting the local fight against breast cancer.
About Dr. Bryan Schneider
Bryan Schneider, MD, is the Director of the Indiana University Health Precision Genomics Program and Associate Director of the Indiana Institute for Personalized Medicine. He is an Associate Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center.
Dr. Schneider cares for breast cancer patients as a medical oncologist and has a special interest in novel therapeutic agents (new treatments) and markers to predict who will best respond or experience side effects. He led a Komen-funded Promise Grant that tested ways to better guide appropriate patient selection for new therapies. He worked with research advocates through Komen’s partner, the Research Advocacy Network, to educate the community about clinical trials and improve enrollment. Under that funding, Dr. Schneider found that Black and African-American patients were more likely to suffer from peripheral neuropathy and hypertension following bevacizumab (Avastin®). He also found several biomarkers linked to higher risks of developing treatment-induced peripheral neuropathy, hypertension, and congestive heart failure.
Dr. Schneider’s current Komen-funded project aims to identify genetic markers that will predict which patients will experience higher levels of toxicity because of chemotherapy.